MUTABILIS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT INFECTIONS CAUSED BY WHO CRITICAL PRIORITY PATHOGENS

By: | Tags: | Comments: 0

Collaboration sets sight on a new age where novel classes of antibiotics and personalized health care options will be available (PARIS, France, February 1st, 2022) – Mutabilis, a biotech based in Romainville, France, announced today that it has entered into a Research Collaboration and License Agreement with Roche on its 2G-Dabocins program.

READ MORE

CARB-X is funding French biotech MUTABILIS to develop a new class of antibacterials to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria

By: | Tags: | Comments: 0

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.

READ MORE